All News

T%20cell.cancer.jpg

With Autoimmunity, Checkpoint Inhibitors Can Be Used

d RheumNow

Among patients with pre-existing autoimmune diseases who developed cancer and were treated with immune checkpoint inhibitors (ICI), flares of the underlying disease and other immune-related adverse events were common, a retrospective study conducted in France showed.

Read Article
osteoporosis.OP_.Drugs_.jpg

Bisphosphonate Use Associated with Reduced Mortality

d Jack Cush, MD

The Journal of Bone and Mineral Research (JBMR) has published a report showing that a reduction in the rate of bone loss by nitrogen bisphosphonates was associated with a 40% lower mortality risk.

Read Article
WAR.RA_.jpg

War on RA – Part 4: Desperado – Time to Open the Gate

d Jack Cush, MD

Do you know what the best-selling album of all time is? Could it be Bing Crosby? U2? Fleetwood Mac? AC/DC? I know, it’s Michael Jackson’s “Thriller” right?

Actually it’s the Eagles Greatest Hits – it surpassed Jackson’s Thriller in August 2019 as the best-selling with a total of 36 million copies sold since it was released in 1976. Wait! Are we not Rheumatologists? Aren’t we supposed to be discussing rheumatoid arthritis?

Read Article
legal.patent.jpg

Enbrel Patent Battle Won by Amgen

d Jack Cush, MD

The ugly, legal, financial underbelly of US biosimilar drug development showed up in court last Friday, when a U.S. judge upheld two of Amgen's patents for Enbrel, thwarting a legal challenge by Novartis/Sandoz over its etanercept-szzs biosimilar, Erelzi. 

Read Article
IPF_0.JPG

RA Disease Activity Drives Lung Complications

d Jack Cush, MD

A longitudinal study from the BRASS registry shows that increase rheumatoid arthritis disease activity increases the risk of RA-associated interstitial lung disease (RA-ILD).

RA patients without RA-ILD at baseline, enrolled in the Brigham RA Sequential Study (BRASS, 2003–2016), were followed from 2003-2016 with serial clinical, DAS28, serologic and imaging assessments.

Read Article
Lilly announces the results of its phase 4 trial comparing Taltz (IL-17) to Tremfya (IL-23) in mod-severe plaque psoriasis. Taltz had superior skin clearance (PASI 100) at week 12, better PASI 75 at week 2 and PASI 90 at weeks 4 and 8. https://t.co/GzfZoepUrK

Links:

Dr. John Cush RheumNow ( View Tweet)

"WAR on RA - Part 4: Desperado" is featured on RheumNow. Why the Eagles and Glenn Fry's death should inspire us to better, greater, more and other superlatives in RA. https://t.co/dgShcQpWHP

Links:

Dr. John Cush RheumNow ( View Tweet)

In GCA/Temporal arteritis, when do you start a DMARD/Biologic?

Dr. John Cush RheumNow ( View Tweet)

Osteoarthritis Iniative study of 3053 #OA pts shows worsening in health related quality of life is most rapid with Female gender, higher BMI, smoking, knee pain, and lower income at baseline. Rapid progressors had higher risk of TKR (HR 6.2;CI 3.6–10.7) https://t.co/73OlM7ymH6

Links:

Dr. John Cush RheumNow ( View Tweet)

Case-control study using the UK Clinical Practice Research database examined 22677 RA pts. 1995–2017) exposed to antibiotics vs ~90K controls shows the risk of RA is 60% higher if Abx exposed (OR 1.60; 95% CI 1.51–1.68) - microbiome changes? https://t.co/ysfEXnRU3c

Links:

Dr. John Cush RheumNow ( View Tweet)

Nearly 30% of presurgical OA (Spine> Hip &Knee) used prescription opioids. Opioid use was greater w/ spine OA (vs knee), obesity, smokers, depression, greater pain, higher TJC, & concurrent use of other pain meds https://t.co/ns6JBB7BXU

Links:

Dr. John Cush RheumNow ( View Tweet)

In GCA/Temporal arteritis, when do you start a DMARD/Biologic?

Dr. John Cush RheumNow ( View Tweet)

"WAR on RA - Part 3: Useless Drugs". Old DMARDs were truly useless (gold, PCM, SSZ, HCQ) but are biologics, combinations, JAKs the answer? Watch here>> https://t.co/5wLDOnXJ1S or Listen on iTunes or SoundCloud https://t.co/SfPQ1sSXgi

Links:

Dr. John Cush RheumNow ( View Tweet)

Osteoarthritis Iniative study of 3053 #OA pts shows worsening in health related quality of life is most rapid with Female gender, higher BMI, smoking, knee pain, and lower income at baseline. Rapid progressors had higher risk of TKR (HR 6.2;CI 3.6–10.7) https://t.co/73OlM7ymH6

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is up! "Tricked Up Lupus Criteria" and more on gout & ULT, IVIG in ANCA vasculitis, NO SIE risk w/ TNFi, and the Best 1st Biologic. Watch the video here>> https://t.co/j1Axn36hL0 or listen to the Podcast on iTUNEs or SoundCloud here>> https://t.co/rjAQmxHce6

Links:

Dr. John Cush RheumNow ( View Tweet)

Amgen wins U.S. patent battle against Novartis over Enbrel patents, delaying Novartis' attempts to launch its etanercept biosimilar Erelzi until (possibly) 2029. Novartis intends to appeal. https://t.co/uoEQJJUf9A

Links:

Dr. John Cush RheumNow ( View Tweet)

Medicare (CMS) has made a decision to cover expensive cancer cell therapies - especially CAR-T therapy - costs re $373,000 for a one-time treatment before hospital costs. https://t.co/M4tkuVt3Gm

Links:

Dr. John Cush RheumNow ( View Tweet)

Check out the "WAR on RA - Part 3: Useless Drugs". We use to have useless drugs (gold, PCM, SSZ, HCQ) but now live in an era of biologics, combinations, JAKs - are these the answer? Watch here>> https://t.co/5wLDOofjTq or Listen on iTunes or SoundCloud https://t.co/SfPQ1sBlRI

Links:

Dr. John Cush RheumNow ( View Tweet)

IL-16 studied in Scleroderma: incr perivasc IL-16 lymphocyte expression w/ more IL-16+ cells in dcSSc vs lcSSc (44 vs 29%, P<0.05). Serum IL-16 levels elevated in SSc pts (297 vs 195 pg/ml) & IL-16 correlated w/ dcSSc, skin score, erythema & pigmentation. https://t.co/lC4nRO6AH0

Links:

Dr. John Cush RheumNow ( View Tweet)

Metanalysis of Early #RA therapy (22 RCTs, 9934 pts), shows that MTX + TNF or non-TNF biologics reduces disease activity and improves remission when compared with MTX monotherapy. 20-57% higher ACR50 rates with Combination Rx https://t.co/iJKmK6uVgg

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×